Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation
PLOS One · 2026
DOI: 10.1371/journal.pone.0355936 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von David Freudenstein und 5 weiteren Autor:innen. Beteiligte Einrichtung: Universitätsklinikum Regensburg Klinik und Poliklinik für Neurologie, Regensburg, Bavaria, Germany. Hauptthemen laut MEDLINE: NF-E2-Related Factor 2, Encephalomyelitis, Autoimmune, Experimental, Th1 Cells, Neuroprotective Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biogen.
Abstract (Originalsprache)
Inflammation and oxidative stress contribute significantly to tissue damage in multiple sclerosis. Fumaric acid esters such as Dimethyl fumarate and Diroximel fumarate (DRF) exhibit immunomodulatory and antioxidative properties, although their mechanisms remain incompletely understood. This study investigated the immunomodulatory and antioxidative mechanisms of fumaric acid esters, with a focus on DRF and its ability to confer neuroprotection in autoimmune neuroinflammation. The MOG-experimental autoimmune encephalomyelitis (EAE) mouse model was employed and DRF was administered orally. In addition to clinical scoring of EAE severity, histological analyses were performed to assess inflammatory infiltration, demyelination, and axonal density. Immune responses were examined via immunophenotyping and cytokine measurements, and mRNA expression was analyzed to evaluate Nrf2 pathway activation. DRF treatment markedly ameliorated clinical EAE severity, reduced spinal cord infiltration of T cells—particularly Th1 cells—and promoted myelin and axonal preservation. Peripheral immune cells from DRF-treated mice produced lower levels of IFN-γ and IL-17A, while Nrf2-dependent antioxidative genes were upregulated in CNS tissue. Our results demonstrate neuroprotective, immunomodulatory, and antioxidative effects of DRF, supporting its role as beneficial modulator in neuroinflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Universitätsklinikum Regensburg Klinik und Poliklinik für Neurologie, Regensburg, Bavaria, Germany.
- Sankt Josef-Hospital Klinik für Neurologie, Bochum, North Rhine-Westphalia, Germany.
ORCID-Profile: David Freudenstein
Förderung
- Biogen
Zitieren
APA
Freudenstein, D., Schneeweiss, A., Krenz, A., Gold, R., Linker, R., & Haase, S. (2026). Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation. PLOS One. https://doi.org/10.1371/journal.pone.0355936
Vancouver
Freudenstein D, Schneeweiss A, Krenz A, Gold R, Linker R, Haase S. Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation. PLOS One. 2026. doi:10.1371/journal.pone.0355936
BibTeX
@article{Freudenstein2026,
author = {Freudenstein, David and Schneeweiss, Anna and Krenz, Adriana and Gold, Ralf and Linker, Ralf and Haase, Stefanie},
title = {Diroximel fumarate confers neuroprotection via reduced Th1 responses and induction of the anti-oxidative Nrf2 pathway in experimental neuroinflammation},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0355936}
}
EUVIMED